Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Pharmagen Laboratories, Inc
WARNING LETTER
•Pharmagen Laboratories, Inc•August 23, 2013

Pharmagen Laboratories, Inc – FDA Warning Letter, Aug 23, 2013

Record Details

This FDA Warning Letter, CMS # 435786, dated October 24, 2014, addresses Pharmagen, Inc. following an inspection from August 5 to August 23, 2013, at their Stamford, CT facility. The inspection revealed serious deficiencies in sterile drug product production.

Key violations include: - **Aseptic Technique Deficiencies:** Operators did not use proper aseptic technique for sterile gowning (e.g., no gloves, no sleeve covers) and leaned on aseptic work surfaces. - **Environmental Control:** Failure to demonstrate adequate protection of ISO 5 areas by hoods, posing a significant contamination risk. - **Unapproved New Drugs/Misbranding:** Prior to registering as a 503B outsourcing facility, Pharmagen produced drugs without valid prescriptions for individually-identified patients, rendering them unapproved new drugs (violating FDCA section 505(a)) and misbranded due to inadequate directions for use (violating section 502(f)(1)). - **Insanitary Conditions:** Sterile drug products were prepared, packed, or held under insanitary conditions, causing them to be adulterated (violating section 501(a)(2)(A)). - **CGMP Violations:** Significant Current Good Manufacturing Practice (CGMP) violations were observed, causing drug products to be adulterated (violating section 501(a

Company
Pharmagen Laboratories, Inc
Inspection date
August 23, 2013
Product type
Drugs
Office
New England District Office
People
  • Scott K. Morton
  • Mutahar Shamsi (District Director)
View Company Profile

ID · 467afdc1-fd4b-4428-99e4-54d8ae98ec94

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 353b21 U.S.C. 35521 U.S.C. 352(f)(1)21 U.S.C. 351(a)(2)(A)21 CFR 211.113(b)21 CFR 211.42(c)(10)(iv)21 CFR 211.28(a)21 CFR 211.167(a)

Full citation text and observation details available on the Dashboard.

Other documents for Pharmagen Laboratories, Inc
  • 483 - 2013-08-23August 23, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pharmagen Laboratories, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.